Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Mantle Cell Lymphoma · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia · Refractory Mantle Cell Lymphoma · Refractory Small Lymphocytic Lymphoma · Small Lymphocytic Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Principal Investigator (Mazyar Shadman, MD, MPH)
Study leads
Mazyar Shadman, MD, MPH
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium